Published in final edited form as:

Nat Rev Cancer. ; 12(2): 104–120. doi:10.1038/nrc3185.

SERIES: Genomic instability in cancer Balancing repair and tolerance of DNA damage caused by alkylating agents

Dragony Fu, Jennifer A. Calvo, and Leona D Samson*

Departments of Biological Engineering and Biology, Center for Environmental Health Sciences, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

Abstract

Alkylating agents comprise a major class of frontline chemotherapeutic drugs that inflict cytotoxic DNA damage as their main mode of action, in addition to collateral mutagenic damage. Numerous cellular pathways, including direct DNA damage reversal, base excision repair (BER), and mismatch repair (MMR) respond to alkylation damage to defend against alkylation-induced cell death or mutation. However, maintaining a proper balance of activity both within and between these pathways is crucial for an organism's favorable response to alkylating agents. Furthermore, an individual's response to alkylating agents can vary considerably from tissue to tissue and from person to person, pointing to genetic and epigenetic mechanisms that modulate alkylating agent toxicity.

Introduction

Alkylating agents are a ubiquitous family of reactive chemicals that transfer alkyl carbon groups onto a broad range of biological molecules, thereby altering their structure and potentially disrupting their function. Alkylating agents are practically unavoidable due to their abundant presence in the environment and within living cells. Major sources of external alkylating agents include constituents of air, water and food such as biological byproducts (e.g. abiotic plant material) and pollutants (e.g. tobacco smoke and fuel combustion products)¹⁻³. Internally, alkylating agents can arise as byproducts of oxidative damage or from cellular methyl donors such as *S*-adenosylmethionine, a common cofactor in biochemical reactions^{4, 5}. Due to the cytotoxic, teratogenic and carcinogenic effects caused by alkylation damage, alkylating agents pose significant threats to human health⁶. In spite of this, certain toxic alkylating agents are commonly used systemically, as chemotherapeutic drugs in cancer patients, with the goal of killing cancer cells⁷. Consequently, while alkylating agents can induce cancer, they are also used to treat cancer. Based upon the double-edged properties of alkylating agents, a greater understanding of the cellular factors that determine biological outcome in response to alkylation damage is particularly relevant for both cancer prevention and cancer therapy, in addition to general human health. The biological response to alkylating agents can be quite complex due to the variety of lesions introduced by a single alkylating agent in combination with the diversity of cellular repair mechanisms and response pathways that can be elicited upon alkylation damage. Here, we focus on the interplay between the multiple cellular factors that respond to DNA alkylation damage and how they collectively determine sensitivity or resistance to alkylating agents.

*To whom correspondence should be addressed: lsamson@mit.edu.

Molecular damage caused by alkylating agents

Alkylating agents react with the ring nitrogens (N) and extracyclic oxygen (O) atoms of DNA bases to generate a variety of covalent adducts ranging from simple methyl groups to complex alkyl additions^{8, 9} (FIG. 1 and 2). The pattern of DNA lesions generated by an alkylating agent depends on the number of reactive sites within the alkylating agent (monofunctional versus bifunctional), its particular chemical reactivity (S_N1 versus S_N2 -type nucleophilic substitution), the type of alkyl group addition (methyl, chloroethyl, etc.) and the DNA substrate (double- or single-stranded). Monofunctional alkylating agents contain one active chemical moiety for modification of a single site in DNA whereas bifunctional alkylating agents contain two reactive groups that can bond with separate DNA bases to form interstrand crosslinks. Whereas S_N2 -alkylating agents mainly target ring nitrogen atoms in DNA bases, S_N1 -alkylating agents can modify these nitrogens plus the extracyclic oxygen groups (FIG. 1). Notably, nearly all chemotherapeutic alkylating drugs currently used in the clinic are S_N1 -type alkylating agents and they can be either monofunctional or bifunctional (FIG. 2).

Due to the high nucleophilic reactivity of the N7-position of guanine in DNA, most monofunctional methylating agents induce the formation of N7-methyl guanine (7meG) as the predominant methylation adduct, accounting for 60-80% of the total alkylation lesions in DNA (FIG. 1). By itself, 7meG does not possess any mutagenic or cytotoxic properties but it is prone to spontaneous depurination to form apurinic/apyrimidinic (AP) sites that are toxic and mutagenic. In addition to 7meG, monofunctional methylating agents can generate N3-methyladenine (3meA) as the other primary N-methylation product, accounting for 10-20% of total methyl adducts⁹. In contrast to the relatively innocuous 7meG lesion, the 3meA lesion is highly cytotoxic since it can block most DNA polymerases and thereby inhibit DNA synthesis^{10, 11}. In single-stranded DNA, the N1-position of adenine and the N3-position of cytosine are also subject to methylation by monofunctional methylating agents to generate the replication blocking and mispairing lesions, 1-methyladenine (1meA) and 3-methylcytosine (3meC)⁸ (FIG. 1). In double-stranded DNA, these sites are protected due to base pairing, but they can be transiently exposed during replication, transcription or recombination.

Amongst the oxygen atoms of DNA, the O^6 -position of guanine represents a major site of methylation by S_N1 -type alkylating agents to generate O^6 -methylguanine (O^6 meG) (FIG. 1). Even though O -alkyl lesions are generated to a much lesser extent than N-alkyl adducts, the induction of O^6 meG lesions by alkylating agents is of great biological relevance because O^6 meG can readily mispair with thymine during DNA replication to cause many of the mutagenic and cytotoxic biological effects of alkylating agents (discussed in detail below). Alkylating agents can also modify other nitrogen and oxygen atoms in DNA besides the aforementioned sites to generate additional toxic and mutagenic lesions (FIG. 1.). However, these lesions are observed at 10 to 100-fold lower levels and represent a minor fraction of total alkylation adducts.

A number of monofunctional S_N1 -methylating agents are currently used as anticancer drugs; these include the triazine family of compounds such as dacarbazine, procarbazine and temozolomide as well as the nitrosourea compound, streptozotocin⁷ (FIG. 2). Due to their chemical reactivity as monofunctional S_N1 -methylating agents, these chemotherapeutic alkylating agents produce significant levels of 7meG, 3meA and O^6 meG lesions as the primary alkylated DNA adducts. The chloroethylating agents represent another major class of monofunctional alkylating agents that react with DNA with a similar specificity as S_N1 -methylating agents except with the addition of a chloroethyl group. The majority of nitrosourea compounds used in the clinic are chloroethylating agents that can modify the N7

and O^6 -positions of guanine to generate chloroethyl adducts (FIG. 2). Significantly, O^6 -chloroethyl guanine (O^6 Cl-ethylG) adducts undergo rapid chemical rearrangement to react with nearby cytosine bases to generate guanine-cytosine (G-C) interstrand DNA crosslinks that are highly cytotoxic.

Bifunctional alkylating agents have similar reactive properties to monofunctional alkylating agents but contain two active moieties that can react with separate bases of DNA to form interstrand crosslinks in addition to monoadducts (FIG. 2). The nitrogen mustards and aziridine compounds are two major classes of bifunctional alkylating drugs used for cancer treatment that can crosslink DNA through a aziridinium-ring intermediate¹². Nitrogen mustard compounds react readily with N7-guanine and to a lesser extent, N3- and N7-adenine, to form bulky N-monoadducts. These adducts can subsequently react with another base to form guanine-guanine (G-G) and guanine-adenine (G-A) interstrand crosslinks (FIG. 2). The nitrogen mustard, mechloroethamine, was the first chemotherapeutic drug used on cancer patients, and derivatives thereof (chlorambucil, cyclophosphamide, melphalan and bendamustine) are prescribed for the treatment of a wide variety of cancers. Aziridine compounds such as altretamine, mitomycin C, and thiotepa use a reaction similar to nitrogen mustards to form G-G or G-A interstrand crosslinks in addition to a variety of monoadducts.

Depending on their position in DNA, the different base adducts introduced by alkylating agents can compromise genome integrity by inducing mutagenesis (thereby promoting cancer induction) and/or blocking essential biological processes such as DNA replication and transcription (potentially leading to cell death) (FIG. 1). Moreover, certain lesions can also be processed into clastogenic and cytotoxic products that can engage other DNA repair pathways or induce programmed cell death. Although we will focus on the biological effects of alkylation damage to genomic DNA, it is important to note that other biological molecules are subject to alkylation damage, including RNA, protein, lipids, and mitochondrial DNA. Thus, a single chemotherapeutic alkylating agent is able to modify a variety of biological molecules to generate a spectrum of lesions that can elicit a number of biological effects.

Complex cellular responses to DNA alkylation damage

Just as a single alkylating agent can cause multiple types of alkylated base lesions, each lesion can be repaired or processed by a number of enzymes and pathways in an effort to counteract the genomic damage induced by alkylating agents, and to protect an organism from alkylation toxicity and mutagenesis (FIG. 3). Thus, diverse cellular repair pathways collectively modulate alkylation sensitivity. This occurs through an overlap in substrates, compensating pathways, processing of intermediates by alternate pathways, or direct crosstalk between pathways. The major repair mechanisms for alkylation damage include direct DNA repair by the AlkB dioxygenase enzyme and the O^6 -methylguanine-DNA methyltransferase (MGMT) repair protein; and by the multistep pathways of base excision repair (BER) and nucleotide excision repair (NER) (FIG. 4). The AlkB enzyme catalyzes direct reversal of certain N-alkyl lesions (e.g. 1meA and 3meC) through a unique oxidative dealkylation reaction, whereas MGMT directly repairs O^6 meG and O^6 Cl-ethylG lesions via transfer of the alkyl group to its active site cysteine residue¹³. The BER pathway plays an important role in the repair of many N-alkyl lesions (e.g. 3meA and 7meG), and the NER pathway may also contribute to the repair of alkylated base lesions^{14, 15}, although this pathway is primarily thought to function in the repair of bulkier base lesions that significantly disrupt DNA-helix structure (e.g. intrastrand crosslinks and UV-induced DNA damage)¹⁶.

Numerous additional repair pathways play significant roles in the cellular response to alkylating agents by processing or bypassing the downstream DNA lesions resulting from DNA transactions at the primary alkyl lesion (e.g. DNA mispairs and replication blocks) or repairing secondary lesions (e.g. single and double strand DNA breaks and crosslinks) (FIG. 3 and 4). The mismatch excision repair (MMR) pathway recognizes and processes DNA base mismatches to remove misincorporated nucleotides; this includes the *O*⁶meG:T mispairs that arise by the incorporation of thymine opposite *O*⁶meG during replication of alkylated DNA¹⁷. Both the homologous recombination (HR) and non-homologous end joining (NHEJ) pathways repair DNA double strand breaks (DSBs); HR uses homologous DNA (sister chromatids) as a template to resynthesize DNA over the break resulting in sister chromatid exchanges (SCEs), whereas NHEJ joins the DNA ends with no or little homology. The translesion DNA synthesis (TLS) pathway employs low-fidelity DNA polymerases to bypass lesions that stall high-fidelity replicative polymerases, thereby alleviating any blocks during DNA replication. Importantly, HR generally results in error-free repair whereas NHEJ and TLS are usually error-prone repair mechanisms that can give rise to mutations. Finally, the Fanconi anaemia pathway coordinates elements of NER, HR and TLS to function in the replication-dependent repair of interstrand DNA crosslinks caused by particular alkylating agents. Due to their widespread involvement in the response to DNA alkylation damage, we will highlight the roles of these DNA repair mechanisms throughout this manuscript while referring readers to more comprehensive reviews dedicated to these pathways¹⁸⁻²⁰.

With the abundance of repair pathways that act upon DNA alkylation damage, it has become clear that an imbalance in any one pathway can affect the overall cellular response, resulting in dramatic effects on the alkylation sensitivity of a cell, a tissue, or a whole organism. Moreover, pathways such as BER and NER require the coordination of multiple enzymatic steps in order to be completed accurately. If an imbalance occurs such that the steps lose coordination, toxic intermediates accumulate that often exhibit greater toxicity than the original DNA base lesion. Furthermore, just as imbalances can occur within a particular DNA repair pathway, they can also occur between different pathways. In this Review, we focus on the distinct and overlapping pathways involved in the repair of 3meA and *O*⁶meG, two representative DNA lesions induced by many cancer chemotherapeutic agents.

Deleterious consequences of BER imbalance

BER is a highly coordinated, multi-step pathway that removes a damaged DNA base (such as an alkylated base) and ultimately replaces it with the correct base (FIG. 3 and 5). The initiation of BER occurs by the recognition and excision of a damaged DNA base lesion by a DNA glycosylase. In humans, there are currently 11 known DNA glycosylases²¹. Here we will focus on the alkyladenine-DNA glycosylase (AAG, also known as MPG or ANPG) as it is responsible for excising the cytotoxic 3meA DNA lesion induced by both S_N1 and S_N2 alkylating agents.

Importantly, every step of BER generates intermediates [AP sites, 5'-deoxyribose phosphate (5'dRP) residues and single strand breaks (SSBs)], which have been shown to be both mutagenic and toxic (FIG. 3 and 5). In fact, the BER intermediates are often more toxic than the initiating DNA base lesion (in this case 3meA, a replication-blocking lesion) presumably because translesion polymerases are capable of bypassing the unrepaired 3meA lesion with varying efficiency and accuracy^{10, 22-24}. Thus, it is essential for BER to be tightly controlled to avoid an accumulation of any of these toxic intermediates. Indeed, another key BER protein, XRCC1, coordinates the DNA processing events of BER by interacting with each of the aforementioned DNA processing enzymes to ensure the proper completion of BER. Accordingly, it has been proposed that the BER pathway functions similar to "passing the

baton” in a relay race; one enzyme complex passes the repair intermediates on to the next enzyme complex, essentially sequestering the intermediates and preventing their toxicity^{25, 26}. Due to the tight coupling of BER processing, an imbalance in any step can therefore alter the phenotypic response to alkylating agents; imbalances can occur when a BER enzyme exhibits an alteration in activity or expression level without compensating changes in the downstream steps of the BER pathway. Although single nucleotide polymorphisms (SNPs) found in BER genes have been associated with an increased risk of multiple types of cancer, additional studies are required to determine the functional consequences and the significance of these SNPs in cancer patients (TABLE 1). However, the potential for imbalanced BER in human cancer is exemplified by the colorectal cancer predisposition syndrome, MAP (MYH-associated polyposis), a consequence of biallelic-inherited mutations in the DNA glycosylase, MYH^{27, 28} (TABLE 1).

BER imbalance in vivo results in detrimental consequences

Modulation of DNA glycosylase activity can have profound effects if the downstream BER pathway is not properly coordinated²⁹⁻³². Pioneer studies in bacteria and yeast have shown that increased DNA glycosylase levels are correlated with increased spontaneous mutagenesis and enhanced sensitivity to the alkylating agent, methyl methanesulfonate (MMS)³³⁻³⁶. This AAG-dependent increase in sensitivity to alkylation has been recapitulated in numerous mammalian cell types, including breast and ovarian cancer cells, astrocytes, and mouse embryonic fibroblasts (MEFs)^{31, 32, 37-40}. Moreover, increased expression of AAG in mammalian cells also results in increased SCEs, chromosome aberrations, inhibition of DNA replication, and a higher number of DNA breaks in response to alkylating agents⁴¹. Even in the absence of alkylating agents, increased AAG DNA glycosylase activity can lead to detrimental effects; AAG activity is correlated with microsatellite instability and increased spontaneous frameshift mutagenesis in yeast and human cells as well as in noncancerous human tissue samples^{42, 43}. Consequently, evidence suggests that altered AAG expression may play a role in various human cancers⁴⁴⁻⁴⁷ (TABLE 1).

The generation of both an *Aag*^{-/-} knockout mouse and a transgenic mouse with increased AAG levels (*Aag* Tg) have provided valuable models to test the consequences of BER imbalance at the whole animal level^{30, 48, 49} (TABLE 2). Since AAG-initiated BER can result in the generation of toxic intermediates following MMS treatment in certain wild-type cells, increased AAG activity would promote the accumulation of toxic intermediates whereas loss of AAG could protect against the formation of these intermediates. Thus, sensitivity to alkylating agents between a wild-type, *Aag*^{-/-} and an *Aag* Tg mouse model would be predicted to correlate with AAG activity levels (as in, sensitivity to alkylating agents: *Aag* Tg > wild-type > *Aag*^{-/-}). Indeed, this pattern of AAG-driven toxicity has been observed repeatedly in multiple tissues (TABLE 2). For example, *ex vivo* bone marrow cell survival assays have shown that *Aag*^{-/-} myeloid precursor cells are resistant, whereas *Aag* Tg cells are ultra-sensitive to alkylating agents compared with wild-type cells (⁵⁰, LDS unpublished data). Moreover, *Aag* Tg mice exhibit vastly increased MMS-induced toxicity in numerous tissues including, spleen, thymus, retina, and cerebellum when compared with wild-type or *Aag*^{-/-} mice (described in BOX 1) (³⁰, LDS unpublished data). Finally, *Aag*^{-/-} mice also exhibit remarkable protection against pancreatic β -cell death after a single high-dose of the β -cell-specific alkylating agent, streptozotocin, as well as a marked delay in the development of streptozotocin-induced glucose intolerance and diabetes^{51, 52}. Thus, in general, *Aag* Tg mice exhibit much greater toxicity to alkylating agents whereas *Aag*^{-/-} mice are either resistant or display no dramatic difference in sensitivity compared with wild-type mice in response to alkylating agents⁵⁰.

Although complete inhibition of BER initiation (as observed in *Aag*^{-/-} mice) protects against alkylation-mediated cell death in numerous tissues, it is important to note that BER inhibition does not confer protection to all alkylating agents or cell types. For example, *Aag*^{-/-} embryonic stem cells as well as MEFs with reduced levels of AAG are actually sensitized to alkylating agents^{49, 53, 54}. Furthermore, *Aag*^{-/-} mice are more susceptible than wild-type mice to alkylation-induced colon cancer initiated by the alkylating agent, azoxymethane (in combination with the inflammatory agent, DSS), indicating that loss of AAG can protect against toxicity but not necessarily carcinogenesis^{55, 56} (TABLE 2). Moreover, it is unknown why only some cells and tissues are sensitive to AAG-mediated alkylation toxicity. For example, the MMS-mediated retinal degeneration observed in mice only occurs in the photoreceptor cells of the outer nuclear layer but not in the adjacent layers of the retina³⁰. While it is possible that different tissues might receive different doses of an alkylating agent leading to differential toxicity, most of the aforementioned alkylating agents act directly, without the need for metabolic activation. Instead, it is more likely that insufficient activity of downstream BER enzymes in the sensitive cell types causes an accumulation of toxic BER intermediates that triggers the majority of AAG-dependent cell death in wild-type and *Aag* Tg mice.

Imbalancing the BER pathway at points downstream of the initiating DNA glycosylase can also sensitize cells to alkylating agents⁵⁷. For example, if AP endonuclease (APE) is limiting for the repair of AP sites (either because glycosylase levels are too high or APE levels are too low), the consequence is an accumulation of mutagenic and cytotoxic AP sites and the subsequent generation of mutations and strand breaks during replication^{34, 58, 59} (FIG. 5). Additionally, inducing BER imbalance through APE inhibition (either by RNA interference or chemical inhibitors) produces similar deleterious results by increasing the number of toxic AP sites and enhancing alkylating agent-sensitivity in numerous cell types^{57, 60-63}. Likewise, the inhibition of Pol β can also imbalance the BER pathway leading to severe biological consequences. For example, MEFs lacking Pol β are normal in viability and growth characteristics but exhibit exquisite sensitivity to alkylating agents⁶⁴. Even partial inhibition of Pol β modulates sensitivity to alkylating agents; a 50% reduction in Pol β , as observed in *Polb*^{+/-} mice, results in increased DNA single-strand breaks, chromosome aberrations and mutagenicity as compared with wild-type mice⁶⁵. Importantly, loss of AAG expression in *Polb*-deficient cells can rescue their sensitivity to alkylating agents, illustrating that the MMS-mediated hypersensitivity and mutagenesis in *Polb*-deficient cells is AAG-dependent. The ability of double mutant MEFs (lacking both AAG and Pol β) to survive alkylating agent exposure indicates that 3meA and other AAG substrates can be bypassed and tolerated by these cells during DNA replication, presumably by the TLS pathway^{10, 24, 66, 67} (FIG. 5). However, if AAG excises 3meA to initiate BER, then downstream BER enzymes such as Pol β are required to complete BER to prevent an accumulation of toxic BER intermediates^{31, 68}.

In addition to being a DNA polymerase, Pol β possesses an intrinsic DNA lyase activity that excises 5' dRP residues in DNA (FIG. 5). Mutational analysis has revealed that the 5' dRP lyase activity of Pol β is also required for alkylation resistance, since disabling just the 5' dRP lyase function of Pol β is sufficient to confer alkylation sensitivity⁶⁹. This finding is notable because it confirms that the 5' dRP species is a toxic BER intermediate. It also demonstrates that, unlike the polymerase function of Pol β , there is no redundant pathway for the 5' dRP removal by Pol β , at least in MEFs. Interestingly, another variant of Pol β that is expressed in some human cancers (termed Pol $\beta\Delta$), is known to have a dominant negative function that essentially inhibits BER⁷⁰. By inhibiting BER, Pol $\beta\Delta$ -expressing cells exhibit increased sensitivity to the alkylating agent, methylnitrosourea (MNU), and *Polb* Δ transgenic mice exhibit greater susceptibility to MNU-induced mammary tumorigenesis compared with wild-type mice⁷⁰. To further underscore the importance of balance within the

BER pathway, increased Pol β activity can also result in deleterious consequences since an increased rate of spontaneous frameshift mutagenesis and microsatellite instability is observed following increased Pol β expression^{71, 72}. Thus, perturbation of either Pol β activity or function in the cell can cause a BER imbalance leading to increased cancer susceptibility and enhanced alkylation sensitivity.

As noted above, the XRCC1 scaffold protein plays a major role in coordinating BER by interacting with the aforementioned DNA processing enzymes at sites of alkylation damage⁷³. Not surprisingly, repression of XRCC1 results in BER imbalance and alkylation sensitivity. For example, *Xrcc1*-deficient cells display impaired BER and accumulate SSBs after alkylating agent treatment⁷⁴. Consequently, *Xrcc1*-deficient cells exhibit severe hypersensitivity to numerous alkylating agents as well as increased genomic instability^{75, 76}. Of note, human monocytes lack detectable levels of XRCC1 and are hypersensitive to alkylating agents⁷⁷, indicating that specific human cell populations can be deficient in BER. Collectively, these data demonstrate that the initiation of the BER pathway by alkylating agents results in an accumulation of toxic and mutagenic BER intermediates that, if uncontrolled, can result in cell death.

The alteration of various BER proteins in cancer patients emphasizes the possibility that imbalanced BER may play a role in cancer etiology (TABLE 1). Indeed, certain polymorphisms in *APE* as well as alterations in APE expression or subcellular localization can either be a risk factor or prognostic indicator for numerous human cancers⁷⁸⁻⁸³. Further, alterations in Pol β are observed in as many as 30% of human cancers⁸⁴ while polymorphisms in XRCC1 are linked to increased risk of numerous types of cancer⁸⁵ (TABLE 1). Thus, a more detailed understanding of how the generation of toxic BER intermediates is regulated in different cell types, both normal and cancerous, will surely contribute to improved cancer chemotherapy with alkylating agents.

Chemical modulation of BER for improved chemotherapy

Inhibitors of BER are being vigorously explored as a mechanism to potentiate the response of cancer cells to alkylating agents. Several inhibitors of APE activity have been identified that sensitize a variety of human cell types to alkylating agents; methoxyamine is one such APE inhibitor that is currently being used in the clinic⁸⁶⁻⁸⁸ (reviewed in ³²). Methoxyamine blocks BER by reacting with an aldehyde-sugar group of the AP site, causing a stable methoxyamine-AP-intermediate adduct that blocks the endonuclease activity of APE. By inhibiting the proper completion of BER, methoxyamine has been shown to potentiate the cytotoxicity of numerous alkylating agents in a variety of cancer cell types and tumor xenograft models^{32, 62, 89}. In addition to altering the APE substrate to prevent DNA incision, direct inhibition of APE could also achieve the same end point of blocking BER. However, given that APE also has an important role in maintaining certain transcription factors, including nuclear factor- κ B and p53 in an active reduced state, care must be taken to inhibit solely the DNA repair function of APE to prevent off-target effects^{90, 91}.

Small-molecule inhibitors of Pol β represent another strategy to effectively imbalance the BER pathway⁹². As expected from the characterization of *Polb*-deficient cells, Pol β inhibitors can increase cellular sensitivity to a variety of alkylating agents⁹³. More recently, highly specific inhibitors of Pol β have been developed that dramatically potentiate temozolomide-sensitivity in colon cancer cells^{94, 95}. Further synergism was observed upon cotreatment with both Pol β inhibitors and temozolomide in cells lacking the homologous recombination factor BRCA2, underscoring the importance of multiple DNA repair pathways in repairing alkylation damage⁹⁶.

Finally, chemical modulation of another DNA repair enzyme, poly(ADP-ribose) polymerase (PARP) has emerged as a potential chemotherapeutic strategy to increase cellular sensitivity to alkylating agents (reviewed in^{97, 98}). PARP plays an important role in the proper repair of SSBs generated during BER by signaling the presence of SSBs to downstream enzymatic repair machinery. The binding of PARP to SSBs leads to PARP activation and to the synthesis of poly(ADP-ribose) chains that facilitate the recruitment of XRCC1, Pol β and ligase to the DNA strand break. Importantly, *Parp1*^{-/-} mice and *Parp1*^{-/-} cells exhibit increased sensitivity to various alkylating agents^{99, 100}, indicating that PARP inhibition can serve as an effective combination therapy with monofunctional alkylating agents. Moreover, the discovery of synthetic lethality in BRCA1 or BRCA2 deficient tumor cells upon treatment with PARP inhibitors has strengthened interest in these inhibitors for single agent therapies^{101, 102}. However, it should be noted that similar to the consequences of altering AAG activity, PARP inhibition can result in dramatically different phenotypic outcomes depending upon the cellular context. For example, PARP inhibition in cells with imbalanced BER (due to altered AAG and Pol β activities) results in resistance to alkylating agents, rather than the alkylation sensitivity observed in other cellular contexts¹⁰³. Thus, it will be clinically important to investigate overall BER function in tumors and patients before using PARP inhibitors¹⁰⁴.

Protecting against highly mutagenic and toxic O⁶meG lesions

As mentioned above, the O⁶meG lesion is the predominant O-methyl adduct but contributes only ~5% of the total lesions induced by methylating agents, compared to the 60-80% represented by N-methyl adducts. However, depending on the particular cell type and an organism's genetic background, the O⁶meG lesion can have dramatic biological effects by eliciting most of the mutagenic and cytotoxic effects associated with S_N1 chemotherapeutic alkylating drugs. Similar to the complex biological response caused by 3meA adducts, it is the interplay between numerous factors in several different pathways that determine the final biological outcome in response to O⁶meG.

The MGMT (alkyltransferase) DNA repair protein plays a pivotal role in governing the fate of organisms after exposure to chemotherapeutic alkylating agents by directly reversing O⁶meG lesions in genomic DNA^{17, 105} (FIG. 3 and 4). The protective effect of MGMT has been demonstrated in striking fashion using transgenic mice that overexpress either the human or bacterial homologue of MGMT in the thymus, liver or colon; these MGMT-overexpressing mice display a significant reduction in alkylation-induced thymic lymphoma, liver tumor development and colon carcinogenesis¹⁰⁶⁻¹¹¹ (TABLE 2). Increased expression of MGMT in skin keratinocytes can also confer protection against epidermal papilloma and tumor formation induced by topical application of alkylating agents¹¹²⁻¹¹⁴. Even in cancer-prone mouse models, increasing the level of MGMT activity is sufficient to decrease spontaneous hepatocellular carcinoma as well as alkylation-induced lymphoma development^{110, 115-118}. Remarkably, MGMT-overexpressing mice display significant preservation of cerebellar development and motor function after treatment with alkylating agents, indicating that MGMT can protect against alkylating agent induced toxicity in the brain as well¹¹⁹. Thus, unlike AAG overexpression that sensitizes many cell types to alkylating agents by producing a BER imbalance, the overexpression of MGMT increases cellular resistance to alkylating agents by increasing the amount of direct repair activity in the cell.

Based upon the protective effects of MGMT expression, it is not surprising that loss of MGMT expression can adversely affect survival upon exposure to alkylating agents. Indeed, *Mgmt*^{-/-} mice exhibit increased levels of cell death in rapidly proliferating tissues such as bone marrow, intestine, thymus and spleen after treatment with alkylating agents (TABLE

2). The tremendous loss of leukocytes and platelets in the haematopoietic stem cell compartment leads to significant ablation of myeloid and lymphoid tissue in *Mgmt*^{-/-} mice treated with alkylating agents¹²⁰⁻¹²². Notably, the severe pancytopenia that develops in *Mgmt*^{-/-} mice after alkylation treatment is lethal and can only be rescued by bone marrow transplantation¹²³. Neuronal cell development in the cerebellum and motor function are also severely disturbed in *Mgmt*^{-/-} mice after treatment with alkylating agents, consistent with a protective function of MGMT in the brain¹¹⁹. In addition to severe tissue loss, alkylation treatment of *Mgmt*^{-/-} mice results in a large number of thymic lymphomas as well as colon carcinomas that are not detected in wild-type mice treated with the same dose of alkylating agents^{55, 124-126}.

Notably, many types of tumors, including brain, breast, colon and lung, display increased MGMT activity when compared to the corresponding normal tissue (reviewed in¹²⁷). While the relation between MGMT activity and clinical outcome remains to be determined for many cancer models, a significant inverse correlation between MGMT expression and patient response has been demonstrated for several types of brain tumors (TABLE 1). In particular, numerous studies have found that pediatric brain tumors exhibit much higher MGMT activity than adults tumors^{128, 129}, leading to a poor response of pediatric tumors to alkylating agents such as temozolomide. Moreover, epigenetic silencing of MGMT expression correlates with a better therapeutic response in patients with glioblastoma¹³⁰, consistent with the absence or low expression of MGMT in promoter hypermethylated tumors conferring sensitivity to S_N1 alkylating agents¹³¹.

Imbalancing MGMT activity to improve chemotherapy

The dramatic effect of MGMT activity on cellular sensitivity and resistance to alkylating agents suggests that modulation of MGMT levels could be used to enhance chemotherapy with alkylating drugs. For example, the inhibition of MGMT activity could be used in the clinic to sensitize cancer cells to alkylating agent-induced toxicity. Indeed, several chemical inhibitors of MGMT activity have been developed and shown to improve the efficacy of alkylating agent-based chemotherapy^{105, 132}. Many of these MGMT inhibitors are *O*⁶-guanine derivatives that take advantage of the self-inactivating DNA repair reaction of MGMT in which the MGMT enzyme is rendered inert after it catalyzes transfer of an aberrant *O*⁶-methyl group onto the active site cysteine in itself. The *O*⁶-guanine derivatives act as substrate analogues to *bona fide* *O*⁶meG targets in DNA by reacting with and inactivating endogenous MGMT enzymes. One of the most potent inhibitors in this class is *O*⁶-benzylguanine (*O*⁶-BG), which has been shown in numerous studies both *in vitro* and *in vivo* to rapidly inactivate MGMT activity. Preclinical studies with a wide range of human tumor xenografts have clearly demonstrated the effectiveness of *O*⁶-BG in sensitizing cancer cells to S_N1-alkylating agents such as BCNU and temozolomide (reviewed in¹³²). Based on its effectiveness, a combination therapy of *O*⁶-BG with BCNU has shown some promise in phase II clinical trials treating patients with recurrent glioblastoma^{133, 134}. Unfortunately, MGMT inhibition in non-tumor cells can lead to significant myelosuppression, a complication that must be rectified to specifically target cancer tissues for sensitization to alkylating agents^{135, 136}.

As a corollary to decreasing MGMT activity in cancer cells, increasing MGMT activity in noncancer cells could improve chemotherapeutic efficacy by protecting normal, bystander cells from alkylating agent-induced cell death and mutation. For example, increasing MGMT activity in mouse bone marrow cells can reduce the myelosuppression associated with alkylating agent treatment, suggesting a possible approach for protecting cancer patients from chemotherapy-associated bone marrow toxicity¹³⁷⁻¹⁴⁰. Of clinical relevance, enhancing MGMT repair activity in haematopoietic cells by stable MGMT overexpression has proven to increase cellular survival during a clinical chemotherapy regimen by

mitigating the toxic effects of O^6 meG adducts¹⁴¹. Chemoprotection has been further demonstrated using immunodeficient mice engrafted with human haematopoietic stem cells overexpressing MGMT, as well as with large animal canine models¹⁴²⁻¹⁴⁶, suggesting feasibility in human cancer patients. In addition, increased MGMT expression in bone marrow cells would also be expected to reduce the incidence of therapy-related secondary cancers. Ideally, one would express an O^6 -BG-resistant form of MGMT in the haematopoietic cells of patients undergoing combination chemotherapy with a S_N1 alkylating agent plus O^6 -BG. Such O^6 -BG-resistant MGMT variants have been extensively characterized and could prove efficacious in future studies¹³².

Multiple cellular pathways determine the biological effects of O^6 meG lesions

Although MGMT is a major protective factor against the deleterious consequences of O -alkylation DNA damage, the relative levels of MGMT in a particular tissue are not necessarily predictive of its sensitivity to alkylating agents when MGMT is absent from that tissue. For example, wild-type bone marrow cells express extremely low levels of MGMT (~100-fold less than liver cells) but they are one of the most sensitive tissues in *Mgmt*^{-/-} mice upon alkylating agent treatment¹²¹. Moreover, cells deficient in MGMT can acquire resistance to alkylating agents that is MGMT-independent. These observations indicate that additional cellular mechanisms play significant roles in the response to alkylation damage that must be taken into consideration when accessing the relative sensitivity of a particular cell or tissue type.

In particular, a number of DNA damage repair and bypass pathways converge on O^6 meG lesions to elicit a variety of downstream effects that can greatly influence the final response to alkylating agents (FIG. 3 and 6). The recruitment of multiple cellular pathways to sites of O^6 meG adducts can be attributed to the DNA replication blocking and miscoding properties of O -methyl lesions, which can inhibit DNA synthesis but ultimately generate DNA mispairs. In the event of replication blocks caused by O^6 meG, the TLS pathway could provide a cellular mechanism to bypass stalled DNA replication forks. Indeed, it has been shown that TLS polymerases such as Pol η , κ and ζ can bypass O^6 meG lesions on DNA templates and that genetic depletion of certain TLS polymerases affects cellular sensitivity to S_N1 alkylating agents^{24, 147-152}. Unfortunately, due to the miscoding properties of O^6 meG adducts, replication past these lesions by either TLS or conventional DNA polymerases results in increased mutagenesis through the generation of O^6 meG:thymine (O^6 meG:T) mispairs^{153, 154} (FIG. 6). As described below, the formation of O^6 meG:T mispairs has dramatic biological consequences by recruiting the MMR pathway that in turn triggers a cascade of DNA processing events that can lead to replication fork collapse, SCEs, chromosome aberrations and cell death.

Among the cellular factors governing sensitivity to chemotherapeutic alkylating agents, the MMR pathway has emerged as a key determinant of the biological effects of O -alkylation damage (reviewed in¹⁵⁵). Although the mechanism by which MMR combines with O -alkyl lesions to modulate the cytotoxicity of alkylating agents is not completely understood, numerous studies have established that recognition of O^6 meG:T mispairs by the MutSa subunit (comprised of MSH2 and MSH6) of the MMR pathway constitutes a critical step for the initiation of programmed cell death in response to alkylation damage¹⁵⁶⁻¹⁶⁰. A possible mechanism to explain the role of MMR in alkylating agent induced cell death involves the repeated processing and regeneration of O^6 meG:T mispairs, ultimately leading to cytotoxic DNA DSBs (FIG. 6). In this model, the MMR machinery would excise the newly synthesized DNA strand containing the mismatched thymine, but then reinsert another thymine across the O^6 meG leading to “futile” cycles of MMR. This constant MMR-dependent processing of DNA at O^6 meG:thymine mispairs would promote the formation of DNA strand gaps¹⁶¹ that can collapse DNA replication forks leading to the formation of

DSBs¹⁶². The conversion of *O*meG lesions into highly cytotoxic DNA DSBs is thought to be the ultimate trigger for cell death by the apoptotic pathway.

In response to collapsed replication forks or DSBs caused by aberrant MMR-dependent processing, error-free recombination via the HR pathway can provide an additional cellular survival mechanism against the cytotoxic effects of *O*-alkyl lesions¹⁶³⁻¹⁶⁵ (FIG. 6). Consistent with the formation of DSBs caused by MMR-dependent processing and subsequent repair by HR, cells that are deficient in the HR pathway display increased sensitivity to *S*_N1 alkylating agents¹⁶⁶⁻¹⁶⁸. While the HR pathway promotes survival by resolving DNA repair intermediates or DSBs caused by MMR processing, this pathway increases the amount of recombination and SCEs¹⁵³. Indeed, MGMT-deficient cells treated with non-toxic doses of *S*_N1-alkylating agents display SCEs after two rounds of replication¹⁶⁹, consistent with recombination occurring at DNA strand breaks induced by aberrant MMR processing. Thus, in addition to MGMT, at least three different DNA damage repair or bypass pathways (MMR, TLS and HR) can converge at sites of *O*-alkylation damage to influence the final biological effects caused by a single type of damaged DNA base lesion (FIG. 6).

In addition to MMR-induced DSB formation, the recognition of *O*meG:T mispairs by MMR proteins could serve, in and of itself, as a sensor for DNA alkylation damage that directly signals for cell death via apoptosis (FIG. 6). In support of MMR-dependent DNA damage signaling, the MutSα complex can physically interact with and activate the DNA damage checkpoint kinase, ataxia-telangiectasia and Rad3-related (ATR), after the formation of *O*meG:T mispairs¹⁷⁰. While it is not known whether ATR activation by MMR is sufficient to trigger apoptosis, it is possible that a combination of MMR signaling and MMR-dependent processing of *O*meG lesions contribute to the activation of apoptosis. Importantly, in either scenario, alkylation-induced cell death is dependent on the MMR-dependent recognition of *O*meG lesions. Thus, in contrast to MGMT, where inhibition or loss of expression increases cellular sensitivity to chemotherapeutic alkylating agents, loss of the MMR pathway produces cells that 'tolerate' *O*-alkyl adducts and are remarkably resistant to the killing effects of *S*_N1-alkylating agents^{160, 171-175}. The protective effect conferred by loss of the MMR pathway has been observed in many different cell types as well as in tissues such as the intestine, colon and haematopoietic stem cell compartment¹⁷⁶⁻¹⁸¹. Notably, the loss of MMR can completely rescue the alkylation-sensitivity of *Mgmt*^{-/-} mice indicating that MMR-dependent recognition of *O*meG lesions is the major contributing factor to cell death and that an entire organism can survive with unrepaired *O*meG lesions present in its genomic DNA as long as these lesions are not processed by the MMR machinery^{122, 182}. However, as expected by the mutagenic properties of *O*-alkylation damage, mice deficient in both MMR and MGMT are extremely sensitive to alkylation-induced lymphoma, demonstrating that the *O*meG adducts that escape MMR processing can generate mutations that lead to cancer^{177, 181, 182}. Collectively, these studies indicate that in certain cellular contexts, *O*-alkyl lesions are the main contributors to the cytotoxicity and mutagenicity of chemotherapeutic alkylating agents with MGMT, MMR, TLS and HR being the pivotal factors in determining eventual toxicity. Importantly, dysregulation in any of these pathways, either through inactivation or overexpression, have been linked to increased cancer susceptibility or cancer resistance to chemotherapeutic alkylating agents (reviewed in ¹⁸³⁻¹⁸⁷) (TABLE 1).

Concluding remarks and future perspectives

It is becoming clear that an organism's response to chemotherapeutic alkylating agents is dictated by the coordination of factors within a particular DNA repair pathway, as well as by the interplay between different DNA repair pathways. As discussed above, an imbalance in

just a single factor can have severe consequences on the health of an organism when exposed to a chemotherapeutic alkylating agent and in some cases, the actions of DNA repair proteins can be highly toxic to the cell rather than protective. Cellular imbalances can arise from genetic differences (mutations, polymorphisms) or epigenetic variation (heterochromatic silencing, microRNA-mediated transcriptional regulation) that can alter the levels of protein expression or activity within a DNA repair pathway¹⁸⁸⁻¹⁹¹. Not surprisingly, these changes in gene expression and regulation can account for the extensive range of alkylating agent-responses exhibited by different cells and tissues within an individual (intraindividual) as well as the broad differences between individuals (interindividual)^{192, 193}. Thus, the next step in understanding how cells respond to chemotherapeutic alkylating agents will involve systems-level analyses (genomics, transcriptomics, proteomics etc.) to provide a global overview of how the levels of DNA repair components can ultimately affect alkylation sensitivity or resistance. The combination of systems-level approaches will improve personalized chemotherapeutic regimens by pinpointing the threshold response of an individual, thereby reducing toxicity or mutagenicity while maximizing tumor cell killing efficiency¹⁰⁴.

In addition to the known DNA repair pathways described above, toxicogenomic studies have revealed novel cellular factors that play major roles in determining an organism's response to alkylating agents¹⁹³⁻¹⁹⁵. The identification of pathways outside of DNA repair that modulate the intra- and interindividual responses to alkylating agents will be of paramount importance for the development of novel chemotherapy regimens that target non-DNA repair pathways with the potential of reducing toxicity and carcinogenicity. Further investigation into the cellular factors and pathways that participate in the repair and response to alkylating agents will provide key insight into the proper use of chemotherapeutic drugs based on alkylating agents. Moreover, these cellular factors and pathways could be altered in normal or cancer cells to improve chemotherapies based on alkylating agents.

Glossary terms

Alkyl	Chemical sidechain that consists only of single-bonded carbon and hydrogen atoms, for example a methyl or ethyl group.
Nucleophilic substitution	Chemical bonding reaction between an electron pair donor nucleophile with an electron pair acceptor electrophile.
Depurination	Loss of a purine base (adenine or guanine) from the DNA backbone through chemical or enzymatic hydrolysis.
Clastogenic	The ability to disrupt or break chromosomes.
Chloroethyl	Alkyl functional group consisting of a chlorine atom bonded to an ethyl carbon group.
Sister chromatid exchanges (SCEs)	Crossing over event between sister chromatids leading to the exchange of homologous stretches of DNA sequence.
Microsatellite instability	Mutations in short motifs of tandemly repeated nucleotides resulting from replication slippage and deficient mismatch repair.
Pancytopenia	Severe reduction in the number of all blood cell types, including red and white blood cells and platelets.
Myelosuppression	Inhibition of blood cell production in the bone marrow.

Apoptosis

A type of caspase-dependent programmed cell death characterized by cell blebbing and DNA fragmentation.

References

1. Ballschmiter K. Pattern and sources of naturally produced organohalogens in the marine environment: biogenic formation of organohalogens. *Chemosphere*. 2003; 52:313–24. [PubMed: 12738255]
2. Hecht SS. DNA adduct formation from tobacco-specific N-nitrosamines. *Mutat Res*. 1999; 424:127–42. [PubMed: 10064856]
3. Hamilton JT, McRoberts WC, Keppler F, Kalin RM, Harper DB. Chloride methylation by plant pectin: an efficient environmentally significant process. *Science*. 2003; 301:206–9. [PubMed: 12855805]
4. Rydberg B, Lindahl T. Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. *EMBO J*. 1982; 1:211–6. [PubMed: 7188181]
5. Taverna P, Sedgwick B. Generation of an endogenous DNA-methylating agent by nitrosation in *Escherichia coli*. *J Bacteriol*. 1996; 178:5105–11. [PubMed: 8752326]
6. Bartsch, H.; O'Neill, IK.; Schulte-Hermann, R.; International Agency for Research on Cancer. Relevance of N-nitroso compounds to human cancer : exposures and mechanisms (International Agency for Research on Cancer. Oxford University Press distributor; Lyon, London: 1987.
7. Kufe, DW., et al., editors. *Cancer Medicine*. 6. BC Decker; Hamilton ON: 2003.
8. Shrivastav N, Li D, Essigmann JM. Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. *Carcinogenesis*. 2010; 31:59–70. [PubMed: 19875697]
9. Drablos F, et al. Alkylation damage in DNA and RNA--repair mechanisms and medical significance. *DNA Repair (Amst)*. 2004; 3:1389–407. [PubMed: 15380096]
10. Johnson RE, Yu SL, Prakash S, Prakash L. A Role for Yeast and Human Translesion Synthesis DNA Polymerases in Promoting Replication through 3-Methyl Adenine. *Mol Cell Biol*. 2007; 27:7198–7205. This study along with references 22-24 show that TLS polymerases play a critical role in alkylating agent sensitivity through the bypass of replication blocking 3-meA lesions. [PubMed: 17698580]
11. Engelward BP, et al. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. *J Biol Chem*. 1998; 273:5412–8. [PubMed: 9479003]
12. Gate, L.; Tew, KD. *Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures*. Mineev, BR., editor. Springer; Netherlands: 2011. p. 61-85.
13. Sedgwick B, Bates PA, Paik J, Jacobs SC, Lindahl T. Repair of alkylated DNA: recent advances. *DNA Repair (Amst)*. 2007; 6:429–42. [PubMed: 17112791]
14. Samson L, Thomale J, Rajewsky MF. Alternative pathways for the in vivo repair of O6-alkylguanine and O4-alkylthymine in *Escherichia coli*: the adaptive response and nucleotide excision repair. *Embo J*. 1988; 7:2261–2267. [PubMed: 3046938]
15. Huang JC, Hsu DS, Kazantsev A, Sancar A. Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts. *Proc Natl Acad Sci U S A*. 1994; 91:12213–7. [PubMed: 7991608]
16. Hanawalt P. Subpathways of nucleotide excision repair and their regulation. *Oncogene*. 2002; 21:8949–8956. [PubMed: 12483511]
17. Kaina B, Christmann M, Naumann S, Roos WP. MGMT: Key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. *DNA Repair (Amst)*. 2007; 6:1079–99. [PubMed: 17485253]
18. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. *Nat Rev Cancer*. 2011; 11:467–480. [PubMed: 21701511]

19. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. *Genes & Development*. 2010; 24:1680–1694. [PubMed: 20713514]
20. Lange SS, Takata K, Wood RD. DNA polymerases and cancer. *Nat Rev Cancer*. 2011; 11:96–110. References 16–20 eloquently describe additional pathways important in the repair and tolerance of DNA alkylation damage that were beyond the scope of this review to describe in detail. [PubMed: 21258395]
21. Svilar D, Goellner EM, Almeida KH, Sobol RW. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. *Antioxid Redox Signal*. 2011; 14:2491–2507. [PubMed: 20649466]
22. Monti P, et al. Rev1 and Polzeta influence toxicity and mutagenicity of Me-lex, a sequence selective N3-adenine methylating agent. *DNA Repair (Amst)*. 2008; 7:431–8. [PubMed: 18182332]
23. Monti P, et al. Mutagenicity of N3-methyladenine: a multi-translesion polymerase affair. *Mutat Res*. 2010; 683:50–6. [PubMed: 19874831]
24. Roos WP, et al. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. *Mol Pharmacol*. 2009; 76:927–34. [PubMed: 19641035]
25. Prasad R, Shock DD, Beard WA, Wilson SH. Substrate Channeling in Mammalian Base Excision Repair Pathways: Passing the Baton. *J Biol Chem*. 2010; 285:40479–40488. [PubMed: 20952393]
26. Mol CD, Izumi T, Mitra S, Tainer JA. DNA-bound structures and mutants reveal abasic DNA binding by APE1 DNA repair and coordination. *Nature*. 2000; 403:451–456. The structural and mutational analysis in this paper provided the basis of the mechanism that toxic BER intermediates are passed from one BER enzyme to another, as reviewed in reference 25. [PubMed: 10667800]
27. Sieber OM, et al. Multiple Colorectal Adenomas, Classic Adenomatous Polyposis, and Germ-Line Mutations in MYH. *N Engl J Med*. 2003; 348:791–799. [PubMed: 12606733]
28. Fleischmann C, et al. Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. *International Journal of Cancer*. 2004; 109:554–558.
29. Rusyn I, et al. Transcriptional networks in *S. cerevisiae* linked to an accumulation of base excision repair intermediates. *PLoS One*. 2007; 2:e1252. [PubMed: 18043759]
30. Meira LB, et al. Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice. *Proc Natl Acad Sci U S A*. 2009; 106:888–93. This publication is first to illustrate that *in vivo*, a deficiency of a DNA glycosylase results in protection from alkylation damage, specifically MMS-mediated retinal degeneration. [PubMed: 19139400]
31. Sobol RW, et al. Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses. *J Biol Chem*. 2003; 278:39951–9. [PubMed: 12882965]
32. Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. *Clin Cancer Res*. 2007; 13:260–7. [PubMed: 17200364]
33. Kaasen I, Evensen G, Seeberg E. Amplified expression of the tag+ and alkA+ genes in *Escherichia coli*: identification of gene products and effects on alkylation resistance. *J Bacteriol*. 1986; 168:642–7. [PubMed: 3536857]
34. Xiao W, Samson L. In vivo evidence for endogenous DNA alkylation damage as a source of spontaneous mutation in eukaryotic cells. *Proc Natl Acad Sci U S A*. 1993; 90:2117–21. [PubMed: 7681584]
35. Glassner BJ, Rasmussen LJ, Najarian MT, Posnick LM, Samson LD. Generation of a strong mutator phenotype in yeast by imbalanced base excision repair. *Proc Natl Acad Sci U S A*. 1998; 95:9997–10002. References 33–35 illustrate that BER intermediates are toxic and mutagenic; an imbalance in the BER pathway results in increased mutagenesis as well as enhanced alkylation sensitivity. [PubMed: 9707589]
36. Posnick LM, Samson LD. Imbalanced base excision repair increases spontaneous mutation and alkylation sensitivity in *Escherichia coli*. *J Bacteriol*. 1999; 181:6763–71. [PubMed: 10542179]
37. Calleja F, Jansen JG, Vrieling H, Laval F, van Zeeland AA. Modulation of the toxic and mutagenic effects induced by methyl methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-alkylpurine-DNA glycosylase. *Mutat Res*. 1999; 425:185–94. [PubMed: 10216211]

38. Rinne M, Caldwell D, Kelley MR. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. *Mol Cancer Ther.* 2004; 3:955–67. [PubMed: 15299078]
39. Rinne ML, He Y, Pachkowski BF, Nakamura J, Kelley MR. N-methylpurine DNA glycosylase overexpression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts. *Nucleic Acids Res.* 2005; 33:2859–67. [PubMed: 15905475]
40. Trivedi RN, et al. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. *Mol Pharmacol.* 2008; 74:505–16. [PubMed: 18477668]
41. Coquerelle T, Dosch J, Kaina B. Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents--a case of imbalanced DNA repair. *Mutat Res.* 1995; 336:9–17. [PubMed: 7528899]
42. Klapacz J, et al. Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. *Mol Cell.* 2010; 37:843–53. [PubMed: 20347426]
43. Hofseth LJ, et al. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. *J Clin Invest.* 1887; 2003; 112:94. This publication clearly describes a correlation between imbalanced base excision repair and microsatellite instability in human tissues.
44. Cerda SR, Turk PW, Thor AD, Weitzman SA. Altered expression of the DNA repair protein, N-methylpurine-DNA glycosylase (MPG) in breast cancer. *FEBS Lett.* 1998; 431:12–8. [PubMed: 9684856]
45. Curtis CD, Thorngren DL, Nardulli AM. Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues. *BMC Cancer.* 2010; 10:9. [PubMed: 20064251]
46. Kim NK, et al. Expression of the DNA repair enzyme, N-methylpurine-DNA glycosylase (MPG) in astrocytic tumors. *Anticancer Res.* 2003; 23:1417–1423. [PubMed: 12820404]
47. Mirabello L, et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. *BMC Cancer.* 2011; 11:209. [PubMed: 21619704]
48. Elder RH, et al. Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. *Mol Cell Biol.* 1998; 18:5828–37. [PubMed: 9742100]
49. Engelward BP, et al. Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. *Proc Natl Acad Sci U S A.* 1997; 94:13087–92. [PubMed: 9371804]
50. Roth RB, Samson LD. 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. *Cancer Res.* 2002; 62:656–60. This reference made the surprising discovery that deficiency in Aag can protect against MMS toxicity in *ex vivo* bone marrow assays. [PubMed: 11830515]
51. Cardinal JW, et al. Increased susceptibility to streptozotocin-induced beta-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice. *Mol Cell Biol.* 2001; 21:5605–13. [PubMed: 11463841]
52. Burns N, Gold B. The effect of 3-methyladenine DNA glycosylase-mediated DNA repair on the induction of toxicity and diabetes by the beta-cell toxicant streptozotocin. *Toxicol Sci.* 2007; 95:391–400. [PubMed: 17098815]
53. Paik J, Duncan T, Lindahl T, Sedgwick B. Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase. *Cancer Res.* 2005; 65:10472–7. [PubMed: 16288039]
54. Engelward BP, et al. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. *EMBO J.* 1996; 15:945–52. Reference 49 and 54 describe the generation of *Aag*^{-/-} ES cells and *Aag*^{-/-} mice, and illustrate that in certain cell types, Aag deficiency results in increased alkylation sensitivity. [PubMed: 8631315]

55. Wirtz S, et al. Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. *Carcinogenesis*. 2010; 31:2111–7. [PubMed: 20732909]
56. Meira LB, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. *J Clin Invest*. 2008; 118:2516–25. [PubMed: 18521188]
57. Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. *Clin Cancer Res*. 1999; 5:2908–17. [PubMed: 10537360]
58. Loeb LA, Preston BD. Mutagenesis by Apurinic/Apyrimidinic Sites. *Annual Review of Genetics*. 1986; 20:201–230.
59. Kunz BA, et al. Specificity of the mutator caused by deletion of the yeast structural gene (APN1) for the major apurinic endonuclease. *Proc Natl Acad Sci U S A*. 1994; 91:8165–8169. [PubMed: 7520176]
60. Luo M, Kelley MR. Inhibition of the human apurinic/aprimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. *Anticancer Res*. 2004; 24:2127–34. [PubMed: 15330152]
61. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. *Mol Cancer Ther*. 2004; 3:679–86. [PubMed: 15210853]
62. Taverna P, et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. *Mutat Res*. 2001; 485:269–81. [PubMed: 11585361]
63. Wilson D, Simeonov A. Small molecule inhibitors of DNA repair nuclease activities of APE1. *Cellular and Molecular Life Sciences*. 2010; 67:3621–3631. [PubMed: 20809131]
64. Sobol RW, et al. Requirement of mammalian DNA polymerase-beta in base-excision repair. *Nature*. 1996; 379:183–6. [PubMed: 8538772]
65. Cabelof DC, et al. Base excision repair deficiency caused by polymerase beta haploinsufficiency: accelerated DNA damage and increased mutational response to carcinogens. *Cancer Res*. 2003; 63:5799–807. [PubMed: 14522902]
66. Sobol RW, et al. Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. *Proc Natl Acad Sci U S A*. 2002; 99:6860–5. [PubMed: 11983862]
67. Poltoratsky V, Horton JK, Prasad R, Wilson SH. REV1 mediated mutagenesis in base excision repair deficient mouse fibroblast. *DNA Repair (Amst)*. 2005; 4:1182–1188. [PubMed: 15950550]
68. Horton JK, Joyce-Gray DF, Pachkowski BF, Swenberg JA, Wilson SH. Hypersensitivity of DNA polymerase beta null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. *DNA Repair (Amst)*. 2003; 2:27–48. [PubMed: 12509266]
69. Sobol RW, et al. The lyase activity of the DNA repair protein [beta] -polymerase protects from DNA-damage-induced cytotoxicity. *Nature*. 2000; 405:807–810. Reference 64 illustrates how Pol β is required for base excision repair and a deficiency in Pol β results in hypersensitivity to alkylating agents. Mutational analysis described in reference 69 demonstrates that the 5' dRP lyase activity of Pol β is sufficient to protect against alkylating agent toxicity. [PubMed: 10866204]
70. Wang L, Bhattacharyya N, Rabi T, Banerjee S. Mammary carcinogenesis in transgenic mice expressing a dominant-negative mutant of DNA polymerase beta in their mammary glands. *Carcinogenesis*. 2007; 28:1356–63. [PubMed: 17166880]
71. Chan K, et al. Overexpression of DNA polymerase beta results in an increased rate of frameshift mutations during base excision repair. *Mutagenesis*. 2007; 22:183–8. [PubMed: 17267816]
72. Yamada NA, Farber RA. Induction of a Low Level of Microsatellite Instability by Overexpression of DNA Polymerase β . *Cancer Res*. 2002; 62:6061–6064. [PubMed: 12414629]
73. Almeida KH, Sobol RW. A unified view of base excision repair: Lesion-dependent protein complexes regulated by post-translational modification. *DNA Repair (Amst)*. 2007; 6:695–711. [PubMed: 17337257]
74. Strom CE, et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. *Nucleic Acids Res*. 2010

75. Zdzienicka MZ, et al. A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges. *Mutagenesis*. 1999; 7:265–269. [PubMed: 1518409]
76. Horton JK, et al. XRCC1 and DNA polymerase [beta] in cellular protection against cytotoxic DNA single-strand breaks. *Cell Res*. 2008; 18:48–63. [PubMed: 18166976]
77. Briegert M, Kaina B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. *Cancer Res*. 2007; 67:26–31. [PubMed: 17210680]
78. Jiang Y, Zhou S, Sandusky GE, Kelley MR, Fishel ML. Reduced Expression of DNA Repair and Redox Signaling Protein APE1/Ref-1 Impairs Human Pancreatic Cancer Cell Survival, Proliferation and Cell Cycle Progression. *Cancer Investigation*. 2010; 28:885–895. [PubMed: 20919954]
79. Al-Attar A, et al. Human apurinic/aprimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. *Br J Cancer*. 2010; 102:704–709. [PubMed: 20087352]
80. Di Maso V, et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. *Mol Med*. 2007; 13:89–96. [PubMed: 17515960]
81. Freitas S, Moore DH, Michael H, Kelley MR. Studies of Apurinic/Apyrimidinic Endonuclease/ref-1 Expression in Epithelial Ovarian Cancer. *Clin Cancer Res*. 2003; 9:4689–4694. [PubMed: 14581338]
82. Kakolyris S, et al. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). *The Journal of Pathology*. 1999; 189:351–357. [PubMed: 10547596]
83. Sweasy JB, Lang T, DiMaio D. Is Base Excision Repair a Tumor Suppressor Mechanism? *Cell Cycle*. 2006; 5:250–259. [PubMed: 16418580]
84. Starcevic D, Dalal S, Sweasy JB. Is There a Link Between DNA Polymerase Beta and Cancer? *Cell Cycle*. 2004; 3:996–999. [PubMed: 15254423]
85. Jiang J, Zhang X, Yang H, Wang W. Polymorphisms of DNA Repair Genes: ADPRT, XRCC1, and XPD and Cancer Risk in Genetic Epidemiology. *Methods in Mol Biology*. 2009; 471:305–333.
86. Simeonov A, et al. Identification and characterization of inhibitors of human apurinic/aprimidinic endonuclease APE1. *PLoS One*. 2009; 4:e5740. [PubMed: 19484131]
87. Bapat A, et al. Novel small-molecule inhibitor of apurinic/aprimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. *J Pharmacol Exp Ther*. 2010; 334:988–98. [PubMed: 20504914]
88. Tang, Jb, et al. N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide. *Neuro-Oncology*. 2011
89. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. *Curr Opin Investig Drugs*. 2004; 5:623–7.
90. Jiang Y, et al. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: Use of APE1 small molecule inhibitors to delineate APE1 functions. *DNA Repair*. 2009; 8:1273–1282. [PubMed: 19726241]
91. Izumi T, et al. Two essential but distinct functions of the mammalian abasic endonuclease. *Proc Natl Acad Sci U S A*. 2005; 102:5739–5743. This study clearly showed that the APE1/Ref-1 contains two domains with independent functions, both of which are essential for cell survival. [PubMed: 15824325]
92. Wilson S, et al. Base excision repair and design of small molecule inhibitors of human DNA polymerase β . *Cellular and Molecular Life Sciences*. 2010; 67:3633–3647. References 89 and 92 illustrate the strategies and progress in developing drugs that inhibit BER as cancer chemotherapeutic agents. [PubMed: 20844920]
93. Hu HY, et al. Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping. *J Biol Chem*. 2004; 279:39736–44. [PubMed: 15258144]

94. Jaiswal AS, et al. A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells. *Mol Cancer Res.* 2009; 7:1973–83. [PubMed: 19996303]
95. Jaiswal AS, et al. DNA Polymerase β as a Novel Target for Chemotherapeutic Intervention of Colorectal Cancer. *PLoS One.* 2011; 6:e16691. [PubMed: 21311763]
96. Stachelek GC, et al. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. *Cancer Res.* 2010; 70:409–17. [PubMed: 20028873]
97. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and beyond. *Nat Rev Cancer.* 2010; 10:293–301. [PubMed: 20200537]
98. Mégnin-Chanet F, Bollet M, Hall J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. *Cellular and Molecular Life Sciences.* 2010; 67:3649–3662. [PubMed: 20725763]
99. de Murcia JM, et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. *Proc Natl Acad Sci U S A.* 1997; 94:7303–7. [PubMed: 9207086]
100. Shibata A, et al. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. *Oncogene.* 2005; 24:1328–37. [PubMed: 15608683]
101. Bryant HE, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. *Nature.* 2005; 434:913–917. [PubMed: 15829966]
102. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature.* 2005; 434:917–921. These seminal papers (references 101 and 102) describe synthetic lethality following treatment of BRCA-deficient cells with Parp inhibitors, resulting in clinical trials testing the efficacy of Parp inhibitors in breast cancer patients, as reviewed in reference 97. [PubMed: 15829967]
103. Jelezcova E, et al. Parp1 activation in mouse embryonic fibroblasts promotes Pol [beta] - dependent cellular hypersensitivity to alkylation damage. *Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.* 2010; 686:57–67.
104. Kelley MR. DNA repair inhibitors: Where do we go from here? *DNA Repair (Amst).* 2011; 10:1183–5. [PubMed: 21963404]
105. Pegg AE. Multifaceted Roles of Alkyltransferase and Related Proteins in DNA Repair, DNA Damage, Resistance to Chemotherapy, and Research Tools. *Chemical Research in Toxicology.* 2011; 24:618–39. [PubMed: 21466232]
106. Nakatsuru Y, et al. O6-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. *Proc Natl Acad Sci U S A.* 1993; 90:6468–72. [PubMed: 8341657]
107. Dumenco LL, Allay E, Norton K, Gerson SL. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. *Science.* 1993; 259:219–22. References 106 and 107 were the first to demonstrate that transgenic MGMT overexpression can confer resistance to alkylating agent-induced carcinogenesis and tumor formation in a mouse. [PubMed: 8421782]
108. Liu L, Allay E, Dumenco LL, Gerson SL. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea-induced thymic lymphomas. *Cancer Res.* 1994; 54:4648–52. [PubMed: 8062258]
109. Allay E, Veigl M, Gerson SL. Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. *Oncogene.* 1999; 18:3783–7. [PubMed: 10391687]
110. Zhou ZQ, et al. Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6- methylguanine-DNA methyltransferase. *Proc Natl Acad Sci U S A.* 2001; 98:12566–71. [PubMed: 11606727]
111. Zaidi NH, et al. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. *Carcinogenesis.* 1995; 16:451–456. [PubMed: 7697797]

112. Becker K, Dosch J, Gregel CM, Martin BA, Kaina B. Targeted expression of human O(6)-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. *Cancer Res.* 1996; 56:3244–9. [PubMed: 8764116]
113. Becker K, et al. DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors. *Carcinogenesis.* 2003; 24:541–546. [PubMed: 12663516]
114. Becker K, Gregel CM, Kaina B. The DNA Repair Protein O6-Methylguanine-DNA Methyltransferase Protects against Skin Tumor Formation Induced by Antineoplastic Chloroethylnitrosourea. *Cancer Res.* 1997; 57:3335–3338. [PubMed: 9269990]
115. Allay E, et al. Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O6-alkylguanine DNA-alkyltransferase. *Oncogene.* 1997; 15:2127–32. [PubMed: 9366529]
116. Qin X, Zhou H, Liu L, Gerson SL. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis. *Carcinogenesis.* 1999; 20:1667–73. [PubMed: 10469609]
117. Qin X, Liu L, Gerson SL. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT. *Oncogene.* 1999; 18:4394–400. [PubMed: 10439048]
118. Reese JS, Allay E, Gerson SL. Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice. *Oncogene.* 2001; 20:5258–63. [PubMed: 11536039]
119. Kisby GE, et al. DNA repair modulates the vulnerability of the developing brain to alkylating agents. *DNA Repair (Amst).* 2009; 8:400–12. [PubMed: 19162564]
120. Tsuzuki T, et al. Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. *Carcinogenesis.* 1996; 17:1215–20. [PubMed: 8681434]
121. Glassner BJ, et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. *Mutagenesis.* 1999; 14:339–47. [PubMed: 10375003]
122. Klapacz J, et al. O6-methylguanine-induced cell death involves exonuclease 1 as well as DNA mismatch recognition in vivo. *Proc Natl Acad Sci U S A.* 2009; 106:576–81. [PubMed: 19124772]
123. Reese JS, Qin X, Ballas CB, Sekiguchi M, Gerson SL. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure. *J Hematother Stem Cell Res.* 2001; 10:115–23. [PubMed: 11276365]
124. Sakumi K, et al. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. *Cancer Res.* 1997; 57:2415–8. [PubMed: 9192819]
125. Iwakuma T, et al. High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. *Carcinogenesis.* 1997; 18:1631–5. [PubMed: 9276640]
126. Hansen RJ, Nagasubramanian R, Delaney SM, Samson LD, Dolan ME. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. *Carcinogenesis.* 2007; 28:1111–6. [PubMed: 17116724]
127. Christmann M, Verbeek B, Roos WP, Kaina B. O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.* 2011; 1816:179–190. This comprehensive review summarizes the vast number of studies on MGMT expression, activity and promoter methylation in human tissues and cancers.
128. Hongeng S, et al. O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. *Clin Cancer Res.* 1997; 3:2459–2463. [PubMed: 9815647]
129. Bobola MS, et al. O6-Methylguanine-DNA Methyltransferase in Pediatric Primary Brain Tumors. *Clin Cancer Res.* 2001; 7:613–619. [PubMed: 11297257]
130. Hegi ME, et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. *N Engl J Med.* 2005; 352:997–1003. [PubMed: 15758010]

131. Christmann M, et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. *Int J Cancer*. 2010; 127:2106–18. [PubMed: 20131314]
132. Kaina B, Margison G, Christmann M. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. *Cellular and Molecular Life Sciences*. 2010; 67:3663–3681. [PubMed: 20717836]
133. Weingart J, et al. Phase I Trial of Polifeprosan 20 With Carmustine Implant Plus Continuous Infusion of Intravenous O6-Benzylguanine in Adults With Recurrent Malignant Glioma: New Approaches to Brain Tumor Therapy CNS Consortium Trial. *J Clin Oncol*. 2007; 25:399–404. [PubMed: 17264335]
134. Quinn JA, et al. Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma. *J Clin Oncol*. 2009; 27:1262–1267. [PubMed: 19204199]
135. Batts E, et al. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. *Cancer Chemotherapy and Pharmacology*. 2007; 60:415–421. [PubMed: 17354015]
136. Gajewski TF, et al. Phase II Trial of the O6-Alkylguanine DNA Alkyltransferase Inhibitor O6-Benzylguanine and 1,3-Bis(2-Chloroethyl)-1-Nitrosourea in Advanced Melanoma. *Clin Cancer Res*. 2005; 11:7861–7865. [PubMed: 16278409]
137. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L. Retrovirus-mediated Expression of a DNA Repair Protein in Bone Marrow Protects Hematopoietic Cells from Nitrosourea-induced Toxicity in Vitro and in Vivo. *Cancer Res*. 1995; 55:2608–2614. [PubMed: 7780976]
138. Maze R, et al. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. *Proc Natl Acad Sci U S A*. 1996; 93:206–210. References 137 and 138 show that transplantation of bone marrow cells overexpressing MGMT can suppress alkylating agent myelosuppression and toxicity in mice. [PubMed: 8552605]
139. Jelinek J, et al. Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human O6-alkylguanine-DNA-alkyltransferase. *Blood*. 1996; 87:1957–1961. [PubMed: 8634444]
140. Allay JA, Koç ON, Davis BM, Gerson SL. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. *Clin Cancer Res*. 1996; 2:1353–1359. [PubMed: 9816307]
141. Schambach A, Baum C. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. *DNA Repair*. 2007; 6:1187–1196. [PubMed: 17482894]
142. Neff T, et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. *J Clin Invest*. 2003; 112:1581–1588. [PubMed: 14617759]
143. Maze R, Hanenberg H, Williams DA. Establishing chemoresistance in hematopoietic progenitor cells. *Mol Med Today*. 1997; 3:350–358. [PubMed: 9269688]
144. Ragg S, Xu-Welliver M, Bailey J. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. *Cancer Res*. 2000; 60:5187–5195. [PubMed: 11016647]
145. Jansen M, et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT^{P140K} into hematopoietic stem cells. *Cancer Gene Ther*. 2002; 9:737–746. [PubMed: 12189523]
146. Neff T, et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. *Blood*. 2005; 105:997–1002. [PubMed: 15494421]
147. Reha-Krantz LJ, Nonay RL, Day RS, Wilson SH. Replication of O6-Methylguanine-containing DNA by Repair and Replicative DNA Polymerases. *J Biol Chem*. 1996; 271:20088–20095. [PubMed: 8702729]
148. Haracska L, Prakash S, Prakash L. Replication past O(6)-methylguanine by yeast and human DNA polymerase ϵ . *Mol Cell Biol*. 2000; 20:8001–7. [PubMed: 11027270]
149. Choi JY, et al. Translesion synthesis across O6-alkylguanine DNA adducts by recombinant human DNA polymerases. *J Biol Chem*. 2006; 281:38244–56. [PubMed: 17050527]

150. Takenaka K, et al. Involvement of Vertebrate Pol κ in Translesion DNA Synthesis across DNA Monoalkylation Damage. *J Biol Chem*. 2006; 281:2000–2004.
151. Haracska L, Prakash S, Prakash L. Yeast DNA Polymerase {zeta} Is an Efficient Extender of Primer Ends Opposite from 7,8-Dihydro-8-Oxoguanine and O6-Methylguanine. *Mol Cell Biol*. 2003; 23:1453–1459. [PubMed: 12556503]
152. Haracska L, Prakash L, Prakash S. Role of human DNA polymerase κ as an extender in translesion synthesis. *Proc Natl Acad Sci U S A*. 2002; 99:16000–16005. [PubMed: 12444249]
153. Kaina B, Gerhard F, Sankar M, Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. *Carcinogenesis*. 1991; 12:1857–1867. [PubMed: 1657427]
154. Lips J, Kaina B. Repair of O6-methylguanine is not affected by thymine base pairing and the presence of MMR proteins. *Mutation Research/DNA Repair*. 2001; 487:59–66.
155. Casorelli I I, Russo MT, M B. Role of mismatch repair and MGMT in response to anticancer therapies. *Anticancer Agents Med Chem*. 2008; 8:368–380. [PubMed: 18473722]
156. Duckett DR, et al. Human MutS α recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. *Proc Natl Acad Sci U S A*. 1996; 93:6443–6447. This study (along with Reference 158) provides a direct link between the MMR pathway and alkylation damage by showing that MutS and MutS α can directly recognize O⁶-meG lesions. [PubMed: 8692834]
157. Meikrantz W, Bergom MA, Memisoglu A, Samson L. O6-alkylguanine DNA lesions trigger apoptosis. *Carcinogenesis*. 1998; 19:369–372. [PubMed: 9498291]
158. Rasmussen LJ, Samson L. The Escherichia coli MutS DNA mismatch binding protein specifically binds O6-methylguanine DNA lesions. *Carcinogenesis*. 1996; 17:2085–2088. [PubMed: 8824540]
159. Dosch J, Christmann M, Kaina B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. *Carcinogenesis*. 1998; 19:567–573. [PubMed: 9600339]
160. Hickman MJ, Samson LD. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. *Proc Natl Acad Sci U S A*. 1999; 96:10764–9. [PubMed: 10485900]
161. Mojas N, Lopes M, Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. *Genes & Development*. 2007; 21:3342–3355. [PubMed: 18079180]
162. Ochs K, Kaina B. Apoptosis Induced by DNA Damage O-Methylguanine Is Bcl-2 and Caspase-9/3 Regulated and Fas/Caspase-8 Independent. *Cancer Res*. 2000; 60:5815–5824. Reference 161 and 162 provide evidence that mismatch repair-dependent processing of O⁶ meG lesions gives rise to cytotoxic DNA strand breaks that trigger apoptotic cell death. [PubMed: 11059778]
163. Rajesh P, Rajesh C, Wyatt MD, Pittman DL. RAD51D protects against MLH1-dependent cytotoxic responses to O(6)-methylguanine. *DNA Repair (Amst)*. 2010; 9:458–67. [PubMed: 20133210]
164. Roos WP, et al. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. *DNA Repair (Amst)*. 2009; 8:72–86. [PubMed: 18840549]
165. Cejka P, Jiricny J. Interplay of DNA Repair Pathways Controls Methylation Damage Toxicity in *Saccharomyces cerevisiae*. *Genetics*. 2008; 179:1835–1844. [PubMed: 18579505]
166. Mirzoeva OK, Kawaguchi T, Pieper RO. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. *Mol Cancer Ther*. 2006; 5:2757–66. [PubMed: 17121922]
167. Tsaryk R, Fabian K, Thacker J, Kaina B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. *Cancer Lett*. 2006; 239:305–13. [PubMed: 16298473]

168. Eich M, Roos WP, Dianov GL, Digweed M, Kaina B. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide. *Mol Pharmacol*. 2010; 78:943–51. [PubMed: 20729302]
169. Kaina B. The interrelationship between SCE induction, cell survival, mutagenesis, aberration formation and DNA synthesis inhibition in V79 cells treated with N-methyl-N-nitrosourea or N-methyl-N'-nitro-N-nitrosoguanidine. *Mutat Res*. 1985; 142:49–54. [PubMed: 3974599]
170. Yoshioka, Ki; Yoshioka, Y.; Hsieh, P. ATR Kinase Activation Mediated by MutSalpa and MutLalpha in Response to Cytotoxic O6-Methylguanine Adducts. *Mol Cell*. 2006; 22:501–510. [PubMed: 16713580]
171. Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. *Nature*. 1993; 362:652–4. [PubMed: 8464518]
172. Koi M, et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. *Cancer Res*. 1994; 54:4308–12. [PubMed: 8044777]
173. de Wind N, Dekker M, Berns A, Radman M, te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. *Cell*. 1995; 82:321–30. References 171-173 show that loss of mismatch repair confers resistance to alkylating agent toxicity in both cells and animals, providing conclusive evidence for the hypothesis that inappropriate mismatch repair-dependent processing of $\mathcal{O}$ meG lesions is a major cytotoxic event associated with alkylating agents. [PubMed: 7628020]
174. Andrew SE, et al. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. *Proc Natl Acad Sci U S A*. 1998; 95:1126–30. [PubMed: 9448296]
175. Hickman MJ, Samson LD. Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. *Mol Cell*. 2004; 14:105–16. [PubMed: 15068807]
176. Toft NJ, et al. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. *Proc Natl Acad Sci U S A*. 1999; 96:3911–5. [PubMed: 10097137]
177. Sansom OJ, Toft NJ, Winton DJ, Clarke AR. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner. *Oncogene*. 2001; 20:3580–4. [PubMed: 11429706]
178. Sansom OJ, Clarke AR. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. *Oncogene*. 2002; 21:5934–9. [PubMed: 12185594]
179. Reese JS, Liu L, Gerson SL. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. *Blood*. 2003; 102:1626–33. [PubMed: 12730104]
180. Sansom OJ, et al. Apoptosis and mutation in the murine small intestine: loss of Mlh1- and Pms2-dependent apoptosis leads to increased mutation in vivo. *DNA Repair (Amst)*. 2003; 2:1029–39. [PubMed: 12967659]
181. Bugni JM, Meira LB, Samson LD. Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. *Oncogene*. 2009; 28:734–41. [PubMed: 19029948]
182. Kawate H, et al. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice. *Carcinogenesis*. 2000; 21:301–5. [PubMed: 10657972]
183. Stallons LJ, McGregor WG. Translesion Synthesis Polymerases in the Prevention and Promotion of Carcinogenesis. *J Nucleic Acids*. 2010; 2010:1–10.
184. Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. *Nat Rev Mol Cell Biol*. 2010; 11:196–207. [PubMed: 20177395]
185. Arana ME, Kunkel TA. Mutator phenotypes due to DNA replication infidelity. *Seminars in Cancer Biology*. 2010; 20:304–311. [PubMed: 20934516]
186. Hewish M, Lord CJ, Martin SA, Cunningham D, Ashworth A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. *Nat Rev Clin Oncol*. 2010; 7:197–208. [PubMed: 20177404]
187. Trainer AH, et al. The role of BRCA mutation testing in determining breast cancer therapy. *Nat Rev Clin Oncol*. 2010; 7:708–717. [PubMed: 21060331]

188. Valeri N, et al. Modulation of mismatch repair and genomic stability by miR-155. *Proc Natl Acad Sci U S A*. 2010; 107:6982–6987. [PubMed: 20351277]
189. Moskwa P, et al. miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors. *Mol Cell*. 2011; 41:210–220. This study shows that microRNAs involved in the expression of DNA damage proteins could be modulated in combination with PARP inhibitors to affect sensitivity to alkylating agents. [PubMed: 21195000]
190. Kiltie, AE., editor. *Molecular Epidemiology of DNA Repair Genes in Bladder Cancer*. Humana Press; Bethesda: 2009.
191. Fenske TS, et al. Identification of Candidate Alkylator-Induced Cancer Susceptibility Genes by Whole Genome Scanning in Mice. *Cancer Res*. 2006; 66:5029–5038. [PubMed: 16707424]
192. Lutz W. A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. *Hum Exp Toxicol*. 2000; 19:566. [PubMed: 11211995]
193. Fry RC, et al. Genomic predictors of interindividual differences in response to DNA damaging agents. *Genes & Development*. 2008; 22:2621–6. [PubMed: 18805990]
194. Begley TJ, Rosenbach AS, Ideker T, Samson LD. Hot spots for modulating toxicity identified by genomic phenotyping and localization mapping. *Mol Cell*. 2004; 16:117–25. [PubMed: 15469827]
195. Ravi D, et al. A Network of Conserved Damage Survival Pathways Revealed by a Genomic RNAi Screen. *PLoS Genet*. 2009; 5:e1000527. [PubMed: 19543366]
196. McKinnon PJ. DNA repair deficiency and neurological disease. *Nature reviews Neuroscience*. 2009; 10:100–12.
197. Robbins JH, Kraemer KH, Lutzner MA, Festoff BW, HG C. Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms and abnormal DNA repair. *Ann Intern Med*. 1974; 80:221–248. [PubMed: 4811796]
198. Savitsky K, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science*. 1995; 268:1749–1753. [PubMed: 7792600]
199. Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. *Brain Research*. 2000; 855:116–123. [PubMed: 10650137]
200. Weissman L, de Souza-Pinto NC, Mattson MP, Bohr VA. DNA base excision repair activities in mouse models of Alzheimer's disease. *Neurobiology of Aging*. 2009; 30:2080–2081. [PubMed: 18378358]
201. Iida T, Furuta A, Nishioka K, Nakabeppu Y, Iwaki T. Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer's disease brain. *Acta Neuropathologica*. 2002; 103:20–25. [PubMed: 11837743]
202. Weissman L, et al. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnesic mild cognitive impairment. *Nucleic Acids Res*. 2007; 35:5545–5555. [PubMed: 17704129]
203. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. *Cell Res*. 2008; 18:27–47. [PubMed: 18166975]
204. Zecca L, Youdim MBH, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. *Nat Rev Neurosci*. 2004; 5:863–873. [PubMed: 15496864]
205. Interthal H, et al. SCAN1 mutant Tdp1 accumulates the enzyme--DNA intermediate and causes camptothecin hypersensitivity. *The EMBO journal*. 2005; 24:2224–33. [PubMed: 15920477]
206. El-Khamisy SF, et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. *Nature*. 2005; 434:108–113. This important reference was the first to link ssDNA break repair with neurodegeneration. [PubMed: 15744309]
207. Lee Y, et al. The genesis of cerebellar interneurons and the prevention of neural DNA damage require XRCC1. *Nat Neurosci*. 2009; 12:973–980. [PubMed: 19633665]
208. Lauritzen KH, et al. Mitochondrial DNA Toxicity in Forebrain Neurons Causes Apoptosis, Neurodegeneration, and Impaired Behavior. *Mol Cell Biol*. 2010; 30:1357–1367. [PubMed: 20065039]
209. Liu L, Qin X, Gerson SL. Reduced lung tumorigenesis in human methylguanine DNA -methyltransferase transgenic mice achieved by expression o transgene within target cell. *Carcinogenesis*. 1999; 20:279–284. [PubMed: 10069465]

BOX 1

Role for base excision repair in neurodegeneration

The link between DNA repair and neurodegeneration (reviewed in ¹⁹⁶) was first established by the discovery of premature nerve cell death and neurological symptoms in Xeroderma Pigmentosum patients¹⁹⁷, and was strengthened when mutations in other DNA damage response proteins were found responsible for the human neurodegenerative syndromes ataxia-telangiectasia (A-T) and A-T-like disease¹⁹⁸. Evidence suggests that imbalanced base excision repair (BER) may also play a role in Alzheimer's disease as the activity of numerous BER proteins is altered in patients with Alzheimer's disease¹⁹⁹⁻²⁰¹. Specifically, Alzheimer's disease patients exhibit decreased DNA glycosylase activity and reduced gap filling activity²⁰². Intriguingly, the alteration of BER activity in Alzheimer's disease patients may be due to the exacerbated age-dependent accumulation of transition metals in diseased brains; these transition metals have been shown to inhibit the function of certain DNA glycosylases^{203, 204}. More recently, additional neurodegenerative syndromes have been linked to mutations in the DNA repair proteins, **aprataxin** (APTX) or **tyrosyl-DNA phosphodiesterase 1** (TDP1)^{205, 206}. APTX and TDP1 process DNA ends following abortive enzymatic reactions; patients with these mutations cannot complete ligation of single-strand breaks (SSBs). Since SSBs are BER intermediates, it is hypothesized that BER imbalance may contribute to the pathology of these disorders. Illustrating the importance of SSB repair in neurons, brain-specific depletion of the BER protein, XRCC1, results in increased DNA damage, cerebellar interneuron degeneration, and ultimately a seizure phenotype similar to epilepsy²⁰⁷. Finally, the mutUNG transgenic mouse model clearly demonstrates the neurotoxicity of BER intermediates²⁰⁸; these mice exhibit a drastic increase in apyrimidinic/apurinic (AP) sites in mitochondrial DNA of the mouse forebrain, ultimately resulting in apoptosis and progressive neuronal atrophy in the hippocampus, culminating with altered cognition and anxiety-like behaviors²⁰⁸.

Imbalanced BER may also play a role in neurodegeneration following alkylation treatment. Treatment of mice with methyl methanesulfonate (MMS) results in severe retinal degeneration³⁰. Strikingly, MMS-induced retinal degeneration is completely suppressed in *Aag*^{-/-} mice, and enhanced in the *Aag* Tg mice indicating that Aag-mediated initiation of BER is essential for this degeneration³⁰ (TABLE 2). A similar phenomenon is observed in cerebellar granule cells; alkylation treatment in mice results in extreme cerebellar toxicity and severely diminished motor function (¹¹⁹, LDS unpublished data). Further demonstrating the importance of the BER pathway in mediating neurodegeneration, *Aag*^{-/-} mice are significantly protected against, and *Aag* Tg are more susceptible to, alkylation-mediated cerebellar toxicity (¹¹⁹, LDS unpublished data). Together, these studies implicate an intriguing role for imbalanced BER pathway in neurodegeneration.

Figure 1. Sites of alkylation on DNA bases

a Monofunctional				Lesions¹
<p><i>Triazene</i></p> <p>Dacarbazine Metastatic melanoma Hodgkin's lymphoma Sarcoma</p>	<p>Procarbazine Malignant gliomas Hodgkin's lymphoma</p>	<p>Temozolomide Malignant gliomas</p>	<p><i>Nitrosourea</i></p> <p>Streptozotocin Pancreatic islet cell cancer</p>	7meG 3meA O ⁶ meG
<p><i>Chloroethylating Nitrosoureas</i></p> <p>ACNU (Nimustine) Brain tumors Solid tumors</p>	<p>BCNU (Carmustine) Brain tumors Lymphomas Melanoma</p>	<p>CCNU (Lomustine) Brain tumors Lymphomas Melanoma</p>	<p>Fotemustine Metastatic melanoma</p>	
b Bifunctional				Lesions
<p><i>Nitrogen mustards</i></p> <p>Mechloroethamine -CH₃ -CH₂CH₂COOH Chlorambucil</p>	<p>Cyclophosphamide</p>	<p>Melfalan</p>	<p>Bendamustine</p>	7-alkylG O ⁶ alkylG G-G x-link G-A x-link
<p><i>Aziridines</i></p> <p>Altretamine Recurrent ovarian cancer</p>	<p>Mitomycin C Breast cancer Gastrointestinal tumors</p>	<p>Thiotepa Breast, ovarian and bladder carcinomas</p>		

Figure 2. DNA lesions induced by monofunctional and bifunctional chemotherapeutic alkylating agents

Figure 3. Mammalian repair and tolerance mechanisms for DNA alkylated bases

Figure 4. DNA repair mechanisms for alkylated bases

Figure 5. Cellular processing and repair of 3meA lesions in DNA

Table 1
Cancer-associated genes involved in alkylation sensitivity

DNA repair protein	Alteration	Cancer	References
BER			
AAG	Single nucleotide polymorphisms and altered expression	Osteosarcoma, breast cancer and astrocytic tumors	44-47
MYH	Autosomal recessive mutations	Colorectal cancer	27,28
APE1	Altered expression or localization	Numerous cancers	78-83
Pol β	Single nucleotide polymorphisms	Numerous cancers	Reviewed in 84
XRCC1	Single nucleotide polymorphisms	Numerous cancers	Reviewed in 85
MGMT	Increased expression and activity	Multiple cancers, glioblastoma, pediatric brain tumors	Reviewed in 127
MMR			
MLH1	Loss of function mutation, loss of expression	Colorectal, endometrial, gastric and urothelial cancers	Reviewed in 186
MSH2			
MSH3			
MSH6			
MLH3			
PMS2			
HR			
BRCA1	Loss of function mutation	Breast, ovarian, fallopian tube, prostate and pancreatic cancer, malignant melanoma, Fanconi Aneamia	Reviewed in 184, 187
BRCA2			
BRIP1			
PALB2			
TLS			
POLH (Pol η)	Autosomal recessive mutation Overexpression	Skin cancer Non-small cell lung cancer, glioma	Reviewed in 183
POLK (Pol κ)			

Table 2
Mouse models of AAG and MGMT*

Mouse model	Organ	Alkylating agent	Phenotype (relative to wildtype)	References
<i>Aag</i> ^{-/-}	Whole animal	MMS	No change in sensitivity	49, 50
	Retina	MMS	Resistant to retinal degeneration	30
	Brain	MAM, MMS	Resistant to cerebellar degeneration	119, unpublished
	Bone marrow (ex vivo)	MMS, TMZ	Increased resistance	50
	Spleen	MMS	Increased mutagenesis	48
	Pancreas	STZ	Resistance to β -cell toxicity and diabetes	51, 52
	Colon	AOM+DSS	Increased susceptibility to colon tumors	55, 56
<i>Aag</i> -Tg	Whole animal	MMS, MNU, AOM+DSS	Increased whole animal sensitivity	unpublished
	Brain, spleen, thymus, pancreas, bone marrow	MMS	Increased cellular toxicity	unpublished
	Retina	MMS	Increased retinal degeneration	30
<i>Mgmt</i> ^{-/-}	Whole animal	BCNU, MNU, STZ	Increased whole animal sensitivity	120-124
	Brain	MAM	Cerebellar folia atrophy, decreased granule cells	119
	Lung	MNU, nitrosamine	Increased tumors	124, 125
	Spleen	MNU, TMZ	Gross atrophy, increased apoptosis, increased mutagenesis	122, 126
	Thymus	MNU	Increased lymphoma, larger tumors	124
	Bone marrow	MNU	Hypocellular, decreased leukocytes, reduced platelet count, impaired HSC reproduction, pancytopenia	120-123
	Liver	nitrosamine	Increased tumors	125
	Colon	MNU	Increased carcinoma	55, 181
MGMT-Tg	Brain	MAM	Normal cerebellar development	119
	Lung	nitrosamine	Decreased mutation, reduced tumors	209
	Skin	MNU	Decreased papillomas, reduced tumors	112-114
	Thymus	MNU	Decreased lymphoma and mutagenesis	107-109, 115-118
	Liver	nitrosamine, spontaneous	Reduced tumor formation	106, 110
	Colon	AOM+DSS	Reduced aberrant crypt foci and K-ras mutation	111

Aag, alkyladenine DNA glycosylase; AOM, azoxymethane; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; DSS, dextran sodium sulfate; HSC, haematopoietic stem cell; MAM, methylazoxymethanol; MGMT, $\mathcal{O}^6$ -methylguanine DNA methyltransferase; MMS, methylmethane sulfonate; MNU, methylnitrosourea; STZ, streptozotocin; TMZ, temozolomide.

* The biological effects of alkyladenine DNA glycosylase (AAG)-overexpression (*Aag*-Tg), Aag-deficiency (*Aag*^{-/-}), $\mathcal{O}^6$ -methylguanine DNA methyltransferase (MGMT)-overexpression (*Mgmt*-Tg) or Mgmt-deficiency (*Mgmt*^{-/-}) in a whole mouse, organ or tissue after treatment with a specific alkylating agent